GNMSF
Price
$204.29
Change
+$4.29 (+2.14%)
Updated
Apr 24 closing price
Capitalization
12.6B
RIGL
Price
$19.05
Change
-$0.01 (-0.05%)
Updated
Apr 25, 02:46 PM (EDT)
Capitalization
340.54M
Ad is loading...

GNMSF vs RIGL

Header iconGNMSF vs RIGL Comparison
Open Charts GNMSF vs RIGLBanner chart's image
Genmab A/S
Price$204.29
Change+$4.29 (+2.14%)
Volume$151
Capitalization12.6B
Rigel Pharmaceuticals
Price$19.05
Change-$0.01 (-0.05%)
Volume$102
Capitalization340.54M
GNMSF vs RIGL Comparison Chart
Loading...
GNMSF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RIGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GNMSF vs. RIGL commentary
Apr 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GNMSF is a StrongBuy and RIGL is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 25, 2025
Stock price -- (GNMSF: $204.29 vs. RIGL: $19.06)
Brand notoriety: GNMSF and RIGL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GNMSF: 7% vs. RIGL: 72%
Market capitalization -- GNMSF: $12.6B vs. RIGL: $340.54M
GNMSF [@Biotechnology] is valued at $12.6B. RIGL’s [@Biotechnology] market capitalization is $340.54M. The market cap for tickers in the [@Biotechnology] industry ranges from $275.91B to $0. The average market capitalization across the [@Biotechnology] industry is $2.16B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GNMSF’s FA Score shows that 0 FA rating(s) are green whileRIGL’s FA Score has 0 green FA rating(s).

  • GNMSF’s FA Score: 0 green, 5 red.
  • RIGL’s FA Score: 0 green, 5 red.
According to our system of comparison, GNMSF is a better buy in the long-term than RIGL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GNMSF’s TA Score shows that 4 TA indicator(s) are bullish while RIGL’s TA Score has 4 bullish TA indicator(s).

  • GNMSF’s TA Score: 4 bullish, 5 bearish.
  • RIGL’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, RIGL is a better buy in the short-term than GNMSF.

Price Growth

GNMSF (@Biotechnology) experienced а +1.84% price change this week, while RIGL (@Biotechnology) price change was +13.12% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.17%. For the same industry, the average monthly price growth was -4.24%, and the average quarterly price growth was -12.55%.

Reported Earning Dates

RIGL is expected to report earnings on Mar 04, 2025.

Industries' Descriptions

@Biotechnology (+7.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GNMSF($12.6B) has a higher market cap than RIGL($341M). RIGL has higher P/E ratio than GNMSF: RIGL (19.25) vs GNMSF (11.07). RIGL YTD gains are higher at: 13.317 vs. GNMSF (-1.490). GNMSF has higher annual earnings (EBITDA): 9.7B vs. RIGL (28.5M). GNMSF has more cash in the bank: 21.1B vs. RIGL (77.3M). RIGL has less debt than GNMSF: RIGL (60M) vs GNMSF (1.03B). GNMSF has higher revenues than RIGL: GNMSF (21.5B) vs RIGL (179M).
GNMSFRIGLGNMSF / RIGL
Capitalization12.6B341M3,695%
EBITDA9.7B28.5M34,025%
Gain YTD-1.49013.317-11%
P/E Ratio11.0719.2558%
Revenue21.5B179M12,011%
Total Cash21.1B77.3M27,296%
Total Debt1.03B60M1,715%
FUNDAMENTALS RATINGS
GNMSF vs RIGL: Fundamental Ratings
GNMSF
RIGL
OUTLOOK RATING
1..100
212
VALUATION
overvalued / fair valued / undervalued
1..100
62
Fair valued
94
Overvalued
PROFIT vs RISK RATING
1..100
9788
SMR RATING
1..100
4199
PRICE GROWTH RATING
1..100
5848
P/E GROWTH RATING
1..100
9699
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GNMSF's Valuation (62) in the null industry is in the same range as RIGL (94) in the Biotechnology industry. This means that GNMSF’s stock grew similarly to RIGL’s over the last 12 months.

RIGL's Profit vs Risk Rating (88) in the Biotechnology industry is in the same range as GNMSF (97) in the null industry. This means that RIGL’s stock grew similarly to GNMSF’s over the last 12 months.

GNMSF's SMR Rating (41) in the null industry is somewhat better than the same rating for RIGL (99) in the Biotechnology industry. This means that GNMSF’s stock grew somewhat faster than RIGL’s over the last 12 months.

RIGL's Price Growth Rating (48) in the Biotechnology industry is in the same range as GNMSF (58) in the null industry. This means that RIGL’s stock grew similarly to GNMSF’s over the last 12 months.

GNMSF's P/E Growth Rating (96) in the null industry is in the same range as RIGL (99) in the Biotechnology industry. This means that GNMSF’s stock grew similarly to RIGL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GNMSFRIGL
RSI
ODDS (%)
Bullish Trend 1 day ago
63%
Bullish Trend 1 day ago
81%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
68%
Bearish Trend 1 day ago
80%
Momentum
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
77%
MACD
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
72%
Bullish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
73%
Bearish Trend 1 day ago
86%
Advances
ODDS (%)
Bullish Trend 1 day ago
66%
Bullish Trend 1 day ago
83%
Declines
ODDS (%)
Bearish Trend 4 days ago
71%
Bearish Trend 10 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
70%
Bearish Trend 1 day ago
72%
Aroon
ODDS (%)
Bearish Trend 1 day ago
75%
Bearish Trend 1 day ago
88%
View a ticker or compare two or three
Ad is loading...
GNMSF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RIGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DFWIX13.970.17
+1.23%
DFA World ex US Core Equity Instl
AWACX20.18N/A
N/A
AB Wealth Appreciation Strategy C
FAMFX24.46N/A
N/A
FAM Small Cap Investor
TISAX58.70N/A
N/A
Nuveen S&P 500 Index I
VESAX17.24N/A
N/A
VELA Small Cap A

GNMSF and

Correlation & Price change

A.I.dvisor indicates that over the last year, GNMSF has been loosely correlated with GMAB. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if GNMSF jumps, then GMAB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GNMSF
1D Price
Change %
GNMSF100%
+2.14%
GMAB - GNMSF
58%
Loosely correlated
+2.04%
RIGL - GNMSF
29%
Poorly correlated
+4.96%
ARCT - GNMSF
28%
Poorly correlated
+1.90%
ATNM - GNMSF
27%
Poorly correlated
-2.31%
AGIO - GNMSF
27%
Poorly correlated
+3.14%
More

RIGL and

Correlation & Price change

A.I.dvisor indicates that over the last year, RIGL has been loosely correlated with MNMD. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if RIGL jumps, then MNMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RIGL
1D Price
Change %
RIGL100%
+4.96%
MNMD - RIGL
39%
Loosely correlated
+5.24%
KYMR - RIGL
38%
Loosely correlated
+9.32%
APGE - RIGL
37%
Loosely correlated
+1.42%
TRDA - RIGL
36%
Loosely correlated
+2.87%
WVE - RIGL
36%
Loosely correlated
N/A
More